Kairos Pharma (KAPA) shares were down 14% in recent Tuesday trading after the company said it received approval to dual list its stock on Upstream, a global trading app for digital securities.
With the dual listing, the company said it can access a global investor base outside the US for additional liquidity and price discovery enhancement.
The Upstream platform facilitates real-time trading and settlement, and ensures a transparent orderbook that does not allow common market manipulations, Kairos said.
Price: 1.43, Change: -0.28, Percent Change: -16.37
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。